Vaccines drive growth
Vaccines are a key driver of company growth. Our goal is to bring 10 new vaccine candidates into clinical trials by 2025. This ambition is fueled by investments in best-in-class science and our mRNA Center of Excellence.
Breakthroughs can come from anywhere
We believe breakthroughs in preventive medicine can come from anywhere. We partner with passionate, innovative medical professionals to bring new vaccines to life.
Does that sound like you? Let’s start a conversation.
Partnering success stories
We’re working with AstraZeneca to protect all infants from Respiratory Syncytial Virus (RSV) by developing and commercializing nirsevimab, the first monoclonal antibody approved for the prevention of RSV.
After years of partnership, we acquired Translate Bio, a clinical-stage mRNA therapeutics company, to strengthen the foundation of our mRNA Center of Excellence. Now, we’re developing a new generation of mRNA vaccines and therapeutics.
We believe vaccines promote health and quality of life. That’s why we acquired Origimm Biotechnology GmbH, a company that discovers bacterial components on the skin that cause disease. These insights underpin the development of vaccines against acne.
Johnson & Johnson
Sanofi and Johnson & Johnson (J&J) are working together to develop and commercialize a potential first-in-class, 9-valent vaccine candidate for extraintestinal pathogenic Escherichia coli (ExPEC), which is currently being evaluated in a Phase 3 clinical study. The agreement between the two companies combines the research and development strength of J&J Sanofi’s worldwide manufacturing footprint and world-class expertise in launching innovative vaccines.
Your partnering lead in Vaccines
For more information, please contact us on Business development team
Global Head of Business Development, Vaccines